18889881171
Kalkine 0
countryflagUS

Ascendis Pharma AS

Healthcare US ASND

158.0USD
0.40(0.25%)

Last update at 2025-05-19T18:57:00Z

Day Range

156.46160.12
LowHigh

52 Week Range

109.96161.00
LowHigh

Fundamentals

  • Previous Close 157.60
  • Market Cap7913.47M
  • Volume162684
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-347.19299M
  • Revenue TTM317.63M
  • Revenue Per Share TTM5.59
  • Gross Profit TTM 39.04M
  • Diluted EPS TTM-7.9

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -474.14400M -577.81700M -383.94400M -419.17400M -218.25000M
Minority interest - - - - 0.00000M
Net income -481.44700M -583.19400M -383.57700M -418.95500M -218.01600M
Selling general administrative 264.41M 221.23M 160.18M 76.67M 48.47M
Selling and marketing expenses - - - - -
Gross profit 222.32M 39.04M 4.25M 6.95M 13.38M
Reconciled depreciation 18.91M 17.96M 15.39M 9.45M 6.69M
Ebit -430.07900M -573.67457M -439.67296M -337.68665M -226.71900M
Ebitda -411.16800M -556.04000M -423.66800M -328.88400M -217.02900M
Depreciation and amortization 18.91M 17.63M 16.00M 8.80M 9.69M
Non operating income net other - - - - 0.00000M
Operating income -455.54100M -561.81400M -451.79200M -330.62000M -226.71900M
Other operating expenses 722.26M 612.99M 459.57M 337.57M 240.09M
Interest expense 44.06M 50.49M 3.91M 1.92M 1.22M
Tax provision 7.30M 5.38M -0.36700M -0.21900M -0.23400M
Interest income 16.86M 7.43M 0.69M 1.81M 10.06M
Net interest income -27.20800M -43.06100M -3.21900M -0.10600M 8.84M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 7.30M 5.38M -0.36700M -0.21900M -0.23400M
Total revenue 266.72M 51.17M 7.78M 6.95M 13.38M
Total operating expenses 677.86M 600.85M 456.05M 337.57M 240.09M
Cost of revenue 44.40M 12.14M 3.52M 0.00000M 0.00000M
Total other income expense net -18.60300M -16.00300M 67.85M -88.55400M 8.47M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -481.44700M -583.19400M -383.57700M -418.95500M -218.01600M
Net income applicable to common shares - -583.19400M -383.57700M -418.95500M -218.01600M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 825.59M 1089.74M 1084.92M 979.79M 676.73M
Intangible assets 0.92M 1.33M 1.78M 2.22M 4.39M
Earning assets - - - - -
Other current assets 38.58M 31.72M 25.23M 13.99M 7.65M
Total liab 971.28M 826.39M 201.29M 141.08M 79.62M
Total stockholder equity -145.69700M 263.35M 883.63M 838.71M 597.11M
Deferred long term liab - - - - 0.00000M
Other current liab 76.19M 44.82M 31.34M 23.68M 13.47M
Common stock 7.75M 7.67M 7.65M 7.22M 6.44M
Capital stock 7.75M 7.67M 7.65M 7.22M 6.44M
Retained earnings -2278.97325M -1860.49300M -1413.85500M -1030.27800M -611.32300M
Other liab - 172.16M 2.96M 3.16M 0.91M
Good will 3.50M 3.50M 3.50M 3.50M 3.50M
Other assets - 1.92M 1.81M 1.38M 1.46M
Cash 392.16M 444.77M 446.27M 584.52M 598.11M
Cash and equivalents - - - - -
Total current liabilities 197.34M 171.27M 100.36M 52.80M 47.99M
Current deferred revenue 1.18M - 2.60M 0.36M 0.86M
Net debt 252.10M 63.61M -341.30600M -492.54200M -561.48700M
Short term debt 25.40M 25.42M 7.00M 6.86M 5.90M
Short long term debt 11.23M 25.42M - - 0.00000M
Short long term debt total 644.26M 508.38M 104.96M 91.97M 36.62M
Other stockholder equity 2132.43M 3.45M 203.71M 851.28M 611.32M
Property plant equipment - 129.09M 126.05M 108.11M 45.07M
Total current assets 702.72M 923.47M 805.89M 740.13M 611.17M
Long term investments 5.69M 30.42M 145.91M 124.46M 15.54M
Net tangible assets - 258.52M 878.36M 832.99M 593.62M
Short term investments 7.28M 290.69M 235.80M 134.28M 0.00000M
Net receivables 55.77M 25.63M 23.19M 7.34M 5.41M
Long term debt 534.25M 482.96M - - 0.00000M
Inventory 208.93M 130.67M 75.41M - 0.00000M
Accounts payable 94.57M 101.03M 59.42M 21.90M 27.77M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income -153.44600M 255.67M 875.99M 831.49M 590.67M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - 7.22M 6.44M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 2.13M 1.92M 1.81M 1.38M 1.46M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 122.87M 166.27M 279.04M 239.66M 65.56M
Capital lease obligations 98.79M - 104.96M 91.97M 36.62M
Long term debt total - - - - 30.72M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 279.03M 61.73M -86.34500M -291.19900M -5.15900M
Change to liabilities - 54.59M 44.39M 7.39M 1.49M
Total cashflows from investing activities - 61.73M -110.57900M -291.19900M -5.15900M
Net borrowings - 496.93M -6.42900M -4.77400M -4.03800M
Total cash from financing activities 134.29M 396.77M 351.39M 602.65M 493.59M
Change to operating activities - -6.40900M -11.23800M -6.35700M 4.77M
Net income -481.44700M -583.19400M -383.57700M -418.95500M -218.01600M
Change in cash -52.60300M -1.50000M -138.25000M -13.58900M 320.24M
Begin period cash flow 444.77M 446.27M 584.52M 598.11M 277.86M
End period cash flow 392.16M 444.77M 446.27M 584.52M 598.11M
Total cash from operating activities -467.36100M -495.69900M -417.64900M -271.54800M -175.93600M
Issuance of capital stock 0.00000M 0.19M 367.88M 638.80M 529.33M
Depreciation 18.91M 17.96M 15.39M 9.45M 6.69M
Other cashflows from investing activities - 9.54M 9.54M 5.05M 5.05M
Dividends paid - 5.06M 33.14M - 0.00000M
Change to inventory -78.25800M -55.26800M -75.40500M -5.48582M -5.63663M
Change to account receivables -32.10121M -11.32333M -6.65900M -1.85966M -1.87156M
Sale purchase of stock -1.81200M -105.30500M -21.60500M 0.00000M 529.33M
Other cashflows from financing activities 8.47M 5.15M 44.68M 26.88M -31.70100M
Change to netincome - 88.15M -0.54900M 138.92M 31.32M
Capital expenditures 2.44M 14.49M 24.23M 21.55M 5.16M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -99.78600M -18.61700M -48.91400M -0.96400M 4.07M
Stock based compensation 66.66M 64.18M 66.83M 53.17M 37.49M
Other non cash items 21.00M 18.60M -67.01200M 85.97M -5.93100M
Free cash flow -469.80300M -510.18800M -441.88300M -293.10000M -181.09500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ASND
Ascendis Pharma AS		 0.40 0.25% 158.00 - - 24.91 14.55 23.43 -20.7458
NVO
Novo Nordisk A/S		 2.24 3.48% 66.61 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.26 5.15% 66.55 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.07 0.02% 438.72 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -0.11 0.02% 594.21 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma AS

Tuborg Boulevard 12, Hellerup, Denmark, 2900

Key Executives

Name Title Year Born
Mr. Jan Moller Mikkelsen Pres, CEO, Member of Exec. Board & Exec. Director 1960
Mr. Michael Wolff Jensen L.L.M. Sr. VP, Chief Legal Officer & Member of the Exec. Board 1971
Dr. Birgitte Volck M.D., Ph.D. Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs 1962
Mr. Scott T. Smith CFO, Sr. VP & Member of Exec. Board 1974
Ms. Lotte Sonderbjerg Chief Admin. Officer, Sr. VP & Member of the Exec. Board 1961
Mr. Peter Rasmussen VP of Fin. & Principal Accounting Officer 1969
Mr. Timothy J. Lee Sr. Director of Investor Relations NA
Mr. Flemming Steen Jensen Sr. VP of Product Supply & Quality 1961
Dr. Kennett Sprogoe Sr. VP and Head of Innovation & Research 1979
Dr. Jens Sigurd Okkels Ph.D. Sr. VP of Product Devel. 1961

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.